RxDoctor Payments DataLook up a doctor →

Ahuva Cices, MD

Dermatology · New York, NYNPI 1578096251

Payments from drug & device makers

$787,277in general payments, 2019–2025

Across 853 payments — averaging $922.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$335K
  • Novartis$176K
  • Pfizer$142K
  • Incyte Corporation$60K
  • UCB SA$19K
  • Sanofi$16K
  • plus $39K from 29 others

What the payments were for

  • Consulting fees$32,26043%
  • Speaking & faculty fees$11,52315%
  • Travel & lodging$3,7045%
  • Food & beverage$27,98837%
  • Education$4011%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$787,277 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$126,838
Medicare patients
303
Services billed
4,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab22$211,427
Dupixent SyringeDupilumab29$119,264
Dupixent PenDupilumab33$115,138
OpzeluraRuxolitinib Phosphate24$46,743
Tacrolimus60$13,193
ZoryveRoflumilast14$11,515
Ketoconazole344$8,157
Clobetasol Propionate116$6,313
Tretinoin46$3,475
Triamcinolone Acetonide209$2,475
Fluocinonide41$1,780
Ammonium Lactate100$1,686
Fluorouracil13$1,122
Metronidazole29$1,058
Clindamycin Phosphate27$907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$59,838$46,74324 claims
Arcutis Biotherapeutics, Inc.Zoryve$1,325$11,51514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →